Measurement of serum antibodies against NY‑ESO‑1 by ELISA: A guide for the treatment of specific immunotherapy for patients with advanced colorectal cancer

Long,Yan‑Yan; Wang,Yu; Huang,Qian‑Rong; Zheng,Guang‑Shun; Jiao,Shun‑Chang

doi:10.3892/etm.2014.1913

Measurement of serum antibodies against NY‑ESO‑1 by ELISA: A guide for the treatment of specific immunotherapy for patients with advanced colorectal cancer

Authors:
- Yan‑Yan Long
- Yu Wang
- Qian‑Rong Huang
- Guang‑Shun Zheng
- Shun‑Chang Jiao
View Affiliations

Affiliations: Department of Medical Oncology, Chinese PLA General Hospital, Beijing 100853, P.R. China, Beijing ImmunoTech Applied Science Ltd., Beijing 100097, P.R. China
Published online on: August 18, 2014 https://doi.org/10.3892/etm.2014.1913
Pages: 1279-1284

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

NY‑ESO‑1 has been identified as one of the most immunogenic antigens; thus, is a highly attractive target for cancer immunotherapy. The present study analyzed the expression of serum antibodies (Abs) against NY‑ESO‑1 in patients with advanced colorectal cancer (CRC), with the aim of guiding the treatment of NY‑ESO‑1‑based specific‑immunotherapy for these patients. Furthermore, the present study was the first to evaluate the kinetic expression of anti‑NY‑ESO‑1 Abs and investigate the possible influencing factors. A total of 239 serum samples from 155 pathologically confirmed patients with advanced CRC (stages III and IV) were collected. The presence of spontaneous Abs against NY‑ESO‑1 was analyzed using an enzyme‑linked immunosorbent assay (ELISA). The results demonstrated that 24.5% (38/155) of the investigated patients were positive for NY‑ESO‑1‑specific Abs. No statistically significant correlations were identified between the expression of anti‑NY‑ESO‑1 Abs and clinicopathological parameters, including age and gender, location, grading, local infiltration, lymph node status, metastatic status and K‑ras mutation status (P>0.05). In 59 patients, the kinetic expression of anti‑NY‑ESO‑1 Abs was analyzed, of which 14 patients were initially positive and 45 patients were initially negative. Notably, 16/59 (27.1%) patients changed their expression status during the study period, and the initially positive patients were more likely to change compared with the initially negative patients (85.7 vs. 8.8%; P<0.001). Therefore, monitoring serum Abs against NY‑ESO‑1 by ELISA is an easy and feasible method. The high expression rate of NY‑ESO‑1‑specific Abs in CRC patients indicates that measuring the levels of serum Abs against NY‑ESO‑1 may guide the treatment of NY‑ESO‑1‑based specific immunotherapy for patients with advanced CRC.

View Figures

View References

1	Siegel R, DeSantis C, Virgo K, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar
3	Lei T, Chen WQ, Zhang SW, et al: Prevalence trend of colorectal cancer in 10 cities and counties in China from 1988 to 2002. Zhonghua Zhong Liu Za Zhi. 31:428–433. 2009.(In Chinese).
4	Li HL, Gao YT, Zheng Y, et al: Incidence trends of colorectal cancer in urban Shanghai, 1973–2005. Zhonghua Yu Fang Yi Xue Za Zhi. 43:875–879. 2009.(In Chinese).
5	He J, Gu D, Wu X, et al: Major causes of death among men and women in China. N Engl J Med. 353:1124–1134. 2005. View Article : Google Scholar : PubMed/NCBI
6	Scanlan MJ, Gure AO, Jungbluth AA, et al: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 188:22–32. 2002. View Article : Google Scholar : PubMed/NCBI
7	Jager E, Chen YT, Drijfhout JW, et al: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 187:265–270. 1998. View Article : Google Scholar
8	Stockert E, Jager E, Chen YT, et al: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 187:1349–1354. 1998. View Article : Google Scholar : PubMed/NCBI
9	Mackensen A, Meidenbauer N, Vogl S, et al: Phase I study of adoptive T-cell therapy using antigen-specific CD8⁺ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol. 24:5060–5069. 2006. View Article : Google Scholar : PubMed/NCBI
10	Gnjatic S, Nishikawa H, Jungbluth AA, et al: NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 95:1–30. 2006. View Article : Google Scholar : PubMed/NCBI
11	Jäger E, Stockert E, Zidianakis Z, et al: Humoral immune responses of cancer patients against ‘Cancer-Testis’ antigen NY-ESO-1: correlation with clinical events. Int J Cancer. 84:506–510. 1999.
12	Kurashige T, Noguchi Y, Saika T, et al: Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res. 61:4671–4674. 2001.PubMed/NCBI
13	Nakada T, Noguchi Y, Satoh S, et al: NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun. 3:102003.PubMed/NCBI
14	Marzouk O and Schofield J: Review of histopathological and molecular prognostic features in colorectal cancer. Cancers (Basel). 3:2767–2810. 2011. View Article : Google Scholar : PubMed/NCBI
15	Chen YT, Scanlan MJ, Sahin U, et al: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 94:1914–1918. 1997. View Article : Google Scholar : PubMed/NCBI
16	Wang Y, Wu XJ, Zhao AL, et al: Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer Immun. 4:112004.PubMed/NCBI
17	Chen HS, Qin LL, Cong X, et al: Expression of tumor-specific cancer/testis antigens in hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi. 11:145–148. 2003.(In Chinese).
18	Kim SH, Lee S, Lee CH, et al: Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung. 187:401–411. 2009. View Article : Google Scholar : PubMed/NCBI
19	Ries J, Mollaoglu N, Vairaktaris E, et al: Diagnostic and therapeutic relevance of NY-ESO-1 expression in oral squamous cell carcinoma. Anticancer Res. 29:5125–5130. 2009.PubMed/NCBI
20	Li M, Yuan YH, Han Y, et al: Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res. 11:1809–1814. 2005. View Article : Google Scholar : PubMed/NCBI
21	Scanlan MJ, Welt S, Gordon CM, et al: Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res. 62:4041–4047. 2002.PubMed/NCBI
22	Wu AW, Gu J, Ji JF, et al: Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients’ prognosis. World J Gastroenterol. 9:1990–1994. 2003.
23	Yarbro JW, Page DL, Fielding LP, et al: American Joint Committee on Cancer prognostic factors consensus conference. Cancer. 86:2436–2446. 1999. View Article : Google Scholar : PubMed/NCBI
24	Jass JR, Love SB and Northover JM: A new prognostic classification of rectal cancer. Lancet. 1:1303–1306. 1987. View Article : Google Scholar : PubMed/NCBI
25	Jager E, Gnjatic S, Nagata Y, et al: Induction of primary NY-ESO-1 immunity: CD8⁺ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1⁺ cancers. Proc Natl Acad Sci USA. 97:12198–12203. 2000.PubMed/NCBI
26	Yuan J, Adamow M, Ginsberg BA, et al: Integrated NY-ESO-1 antibody and CD8⁺ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA. 108:16723–16728. 2011.PubMed/NCBI
27	Tsuji T and Gnjatic S: Split T-cell tolerance as a guide for the development of tumor antigen-specific immunotherapy. Oncoimmunology. 1:405–407. 2012. View Article : Google Scholar : PubMed/NCBI